Loading
A senior breast cancer specialist who has led Japanese arms of adjuvant and metastatic breast cancer trials for two decades.
Shinji Ohno is Director of the Breast Oncology Center at the Cancer Institute Hospital of JFCR in Tokyo. A senior breast cancer specialist, he has led Japanese arms of adjuvant and metastatic breast cancer trials for two decades, serving as an investigator on CDK4/6, HER2 and adjuvant endocrine trials with Japanese cohorts. His publications include the ESMO Clinical Practice Guidelines for early and primary breast cancer and a machine learning study predicting disease-free survival and brain metastasis in HER2-positive patients treated with neoadjuvant chemotherapy plus trastuzumab. His interests are breast cancer, adjuvant therapy and clinical trials.
| Title | Journal | Year |
|---|---|---|
| Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2019 |
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 |
| Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm | Breast Cancer Research and Treatment | 2018 |
Shares Breast cancer research and treatment, HR-positive / HER2-negative breast cancer.
Shares Cancer Institute Hospital of JFCR, HR-positive / HER2-negative breast cancer.
Shares Breast cancer research and treatment, HER2-positive breast cancer.
Shares Breast cancer research and treatment, HR-positive / HER2-negative breast cancer.
Shares Breast cancer research and treatment, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.